Red­hill spikes — briefly — on pos­i­tive Crohn's da­ta; Dai­ichi inks glob­al li­cens­ing deal with Gly­co­tope

→ Shares of Is­rael’s Red­hill Bio­Phar­ma $RDHL spiked Mon­day morn­ing — then quick­ly be­gan to slide back — af­ter the biotech laid out da­ta demon­strat­ing how their drug for Crohn’s dis­ease edged out the place­bo arm in their first Phase III study.

The drug is RHB-104, an an­tibi­ot­ic com­bi­na­tion that was based on Red­hill’s the­o­ry that Crohn’s is caused by a bac­te­r­i­al in­fec­tion. In their Phase III re­searchers say that 37% of the pa­tients in their drug arm achieved re­mis­sion at 26 weeks, com­pared to a hefty 23% in the place­bo group. That re­sult­ed in a pos­i­tive p val­ue of 0.013.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.